These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 5022098)

  • 1. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients.
    Curzon G; Kantamaneni BD; Trigwell J
    Clin Chim Acta; 1972 Mar; 37():335-41. PubMed ID: 5022098
    [No Abstract]   [Full Text] [Related]  

  • 2. A reliable and simple method for simultaneous determination of DOPA and 3-O-methyldopa in plasma and brain.
    Fahn S; Prasad AL; Delesie R
    Anal Biochem; 1972 Apr; 46(2):557-75. PubMed ID: 4337048
    [No Abstract]   [Full Text] [Related]  

  • 3. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS; Muenter MD; Tyce GM; Owen CA
    Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fluroimetric determination of sub-micromolar amounts of DOPA in plasma].
    Geissbuehler F
    Clin Chim Acta; 1973 May; 45(4):423-7. PubMed ID: 4730212
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinsonism treated with 3-O-methyldopa.
    Calne DB; Reid JL; Vakil SD
    Clin Pharmacol Ther; 1973; 14(3):386-9. PubMed ID: 4698566
    [No Abstract]   [Full Text] [Related]  

  • 8. [Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].
    Lhermitte F; Agid Y; Feuerstein C; Serre F; Signoret JL; Studler JM; Bonnet AM
    Rev Neurol (Paris); 1977; 133(8-9):445-54. PubMed ID: 929037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid estimation of DOPA in physiological fluids using the amino acid analyzer.
    Hare TA; Vogel WH
    Biochem Med; 1970 Nov; 4(3):277-81. PubMed ID: 5524069
    [No Abstract]   [Full Text] [Related]  

  • 10. [Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].
    Geissbühler F; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Clin Chim Acta; 1971 Jun; 33(1):111-5. PubMed ID: 5097993
    [No Abstract]   [Full Text] [Related]  

  • 11. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
    Fahn S
    Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
    [No Abstract]   [Full Text] [Related]  

  • 12. Brain tissue and plasma assay of L-DOPA and alpha-methyldopa metabolites by high performance liquid chromatography with electrochemical detection.
    Freed CR; Asmus PA
    J Neurochem; 1979 Jan; 32(1):163-8. PubMed ID: 759567
    [No Abstract]   [Full Text] [Related]  

  • 13. Determination of free DOPA and 3-O-methyl-DOPA in human plasma by high-performance liquid chromatography with electrochemical detection.
    Melzi d'Eril GV; Rizzo V
    J Chromatogr; 1991 Aug; 553(1-2):265-9. PubMed ID: 1787158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of L-dopa in patients with Parkinson's disease.
    Mena MA; Muradas V; Bazan E; Reiriz J; de Yebenes JG
    Adv Neurol; 1987; 45():481-6. PubMed ID: 2950730
    [No Abstract]   [Full Text] [Related]  

  • 15. 3-O-methyl metabolites of catecholamines: automated fluorometric assay and their plasma levels in patients receiving levodopa and carbidopa.
    Prasad AL; Fahn S
    Biochem Med; 1974 Feb; 9(2):136-47. PubMed ID: 4822034
    [No Abstract]   [Full Text] [Related]  

  • 16. Simple gas chromatographic analysis of plasma dopa and dopamine.
    Mizuno Y
    Clin Chim Acta; 1977 Jan; 74(1):11-9. PubMed ID: 832410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis in human plasma of 3-methoxytyrosine: a metabolite of DOPA.
    Fellman JH; Joyce JR; Strandholm JJ
    Clin Chim Acta; 1971 Apr; 32(2):313-5. PubMed ID: 5122233
    [No Abstract]   [Full Text] [Related]  

  • 18. Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Jun; 45(6):438-43. PubMed ID: 5425103
    [No Abstract]   [Full Text] [Related]  

  • 19. Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.
    Rivera-Calimlim L
    Br J Pharmacol; 1974 Feb; 50(2):259-63. PubMed ID: 4425764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.